{"id":"W4365811156","doi":"10.1002/ehf2.14363","title":"Optimizing Outcomes in Heart Failure: 2022 and Beyond","year":2023,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"National Heart, Lung, and Blood Institute; Respicardia; American Regent; Abbott Vascular; National Institutes of Health; I.M. Sechenov First Moscow State Medical University; Universidade do Porto; Vifor Pharma; Rigshospitalet; MyoKardia; Novo Nordisk; Medizinischen Hochschule Hannover; University of Glasgow; Pfizer; Moderna; National and Kapodistrian University of Athens; Universidad de Navarra; Impulse Dynamics; Sarepta Therapeutics; Cytokinetics; Alnylam Pharmaceuticals; University of Cyprus; Linköpings Universitet; Amgen; European Society of Cardiology; Westfälische Wilhelms-Universität Münster; Boston Scientific Corporation; Baxter Healthcare Corporation; Cyprus University of Technology; King's College London; Daiichi Sankyo Europe; Servier; Gilead Sciences; Relypsa; Università degli Studi di Pavia; Cairo University; Sanofi; Sanofi Pasteur; Universitair Medisch Centrum Groningen; Celladon Corporation; LivaNova; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Guideline; Heart failure; Intensive care medicine; Quality (philosophy); Health care; Quality of life (healthcare); Best practice; Nursing; Cardiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007922603,0.0009999312,0.00407859,0.001083929,0.0001683154,0.0001288131,0.0001830886,0.000678411,0.0004476168],"category_scores_gemma":[0.0001691172,0.0007839603,0.0008062094,0.001126633,0.0001143832,0.0001877469,0.0003852137,0.001220624,0.001519366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003069562,"about_ca_system_score_gemma":0.000369356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001073729,"about_ca_topic_score_gemma":0.0005193264,"domain_scores_codex":[0.9957761,0.0002707061,0.001122393,0.001170135,0.0006517969,0.001008892],"domain_scores_gemma":[0.9979749,0.0003780181,0.0001631722,0.0009524963,0.00005405251,0.0004773539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000237527,0.0004761232,0.002855221,0.02805075,0.001367608,0.000825935,0.0003783933,0.000001656548,0.000006534209,0.0005874367,0.8654324,0.09999414],"study_design_scores_gemma":[0.001181217,0.0002084946,0.0001440011,0.007280653,0.001007904,0.0001702704,0.0002108121,0.000005819563,0.000001338883,0.00002781784,0.9891584,0.0006033014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005583935,0.9424334,0.000006988249,0.05216284,0.0003971587,0.004129093,0.00005864269,0.0004479167,0.0003081438],"genre_scores_gemma":[0.00001642149,0.957065,0.02945542,0.001042673,0.0003786933,0.0007607746,0.0004091386,0.0002845049,0.01058741],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1237259,"threshold_uncertainty_score":0.9994611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03891397122767665,"score_gpt":0.3339422766952516,"score_spread":0.2950283054675749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}